Reconstruction in women with T4 breast cancer after neoadjuvant chemotherapy: When is it safe? Journal Article
| Authors: | Pawloski, K. R.; Barrio, A. V.; Gemignani, M. L.; Sevilimedu, V.; Le, T.; Dayan, J.; Morrow, M.; Tadros, A. B. |
| Article Title: | Reconstruction in women with T4 breast cancer after neoadjuvant chemotherapy: When is it safe? |
| Abstract: | Background: Despite limited evidence regarding its safety, immediate reconstruction (IR) is increasingly offered to women with T4 breast cancer. We compared outcomes after IR, delayed reconstruction (DR), and no reconstruction (NR) in patients treated with neoadjuvant chemotherapy (NAC) and postmastectomy radiation therapy (PMRT) for T4 disease. Study Design: We retrospectively identified consecutive women with T4 tumors treated with trimodality therapy from January 2007 through December 2019. Clinicopathologic characteristics, complications requiring reoperation, time to PMRT, and recurrence patterns were compared. The cumulative incidence of local recurrence (LR) was estimated using Kaplan-Meier methods. Results: Of the 269 women identified, the median (IQR) age was 52 (45–62) years; 164 women (61%) had T4d disease. Forty-five women (17%) had IR, 41 (15%) had DR, and 183 (68%) had NR. IR was independently associated with T4a-c disease (odds ratio [OR], 5.75; 95% CI, 2.57–12.87; p < 0.001) and younger age (OR 0.91; 95% CI, 0.86–0.94; p < 0.001). The risk of complications after IR was 22% overall and 46% in T4d patients (6/13), compared with 4.4% overall for NR and 7.3% for DR (p < 0.001). IR was associated with >8-week interval to PMRT (p < 0.001). At a median (range) follow-up of 4.2 (0.2–13) years, the median time to first recurrence was 18 months and was similar between groups (p = 0.13). The cumulative incidence of LR was 16% for T4d disease and 2.2% for T4a-c disease (p < 0.001). Conclusions: After IR, women with T4 tumors, particularly T4d disease, experienced delayed initiation of adjuvant treatment and substantial morbidity, suggesting that an interval of >18 months between mastectomy and reconstruction is advisable. © 2021 American College of Surgeons |
| Journal Title: | Journal of the American College of Surgeons |
| Volume: | 233 |
| Issue: | 2 |
| ISSN: | 1072-7515 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2021-08-01 |
| Start Page: | 285 |
| End Page: | 293 |
| Language: | English |
| DOI: | 10.1016/j.jamcollsurg.2021.04.016 |
| PUBMED: | 33957258 |
| PROVIDER: | scopus |
| PMCID: | PMC9466002 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 August 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work